Literature DB >> 19022708

Highlights of a workshop to discuss targeting inflammation in cystic fibrosis.

Katharine H Banner1, Hugo De Jonge, Stuart Elborn, Ellena Growcott, Erich Gulbins, Mike Konstan, Rick Moss, Chris Poll, Scott H Randell, Adriano G Rossi, Lorraine Thomas, David Waltz.   

Abstract

A workshop to discuss anti-inflammatory approaches in the treatment of CF was held at Novartis Institutes for Biomedical Research (NIBR, Horsham, UK) in March 2008. Key opinion leaders in the field (Hugo De Jonge, Stuart Elborn, Erich Gulbins, Mike Konstan, Rick Moss, Scott Randell and Adriano Rossi), and NIBR scientists were brought together to collectively address three main aims: (i) to identify anti-inflammatory targets in CF, (ii) to evaluate the pros and cons of targeting specific cell types and (iii) to discuss model systems to profile potential therapeutic agents. The highlights of the workshop are captured in this review.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19022708      PMCID: PMC4133129          DOI: 10.1016/j.jcf.2008.10.002

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  76 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

2.  Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects.

Authors:  Michael W Konstan; Jeanne E Krenicky; Marcie R Finney; H Lester Kirchner; Kathleen A Hilliard; Jay B Hilliard; Pamela B Davis; Charles L Hoppel
Journal:  J Pharmacol Exp Ther       Date:  2003-06-13       Impact factor: 4.030

3.  T lymphocytes and activated eosinophils in airway mucosa in fatal asthma and cystic fibrosis.

Authors:  M Azzawi; P W Johnston; S Majumdar; A B Kay; P K Jeffery
Journal:  Am Rev Respir Dis       Date:  1992-06

4.  Inflammatory markers of lung disease in adult patients with cystic fibrosis.

Authors:  Hara Levy; Leslie A Kalish; Ian Huntington; Nathaniel Weller; Craig Gerard; Edwin K Silverman; Juan C Celedón; Gerald B Pier; Scott T Weiss
Journal:  Pediatr Pulmonol       Date:  2007-03

Review 5.  Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis.

Authors:  Michael W Konstan; Pamela B Davis
Journal:  Adv Drug Deliv Rev       Date:  2002-12-05       Impact factor: 15.470

6.  Antioxidants in cystic fibrosis. Conclusions from the CF antioxidant workshop, Bethesda, Maryland, November 11-12, 2003.

Authors:  André M Cantin; Terry B White; Carroll E Cross; Henry Jay Forman; Ronald J Sokol; Drucy Borowitz
Journal:  Free Radic Biol Med       Date:  2006-09-29       Impact factor: 7.376

Review 7.  Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action.

Authors:  Masaharu Shinkai; Markus O Henke; Bruce K Rubin
Journal:  Pharmacol Ther       Date:  2007-12-15       Impact factor: 12.310

Review 8.  TLR2 - promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity.

Authors:  Ulrich Zähringer; Buko Lindner; Seiichi Inamura; Holger Heine; Christian Alexander
Journal:  Immunobiology       Date:  2008-03-28       Impact factor: 3.144

9.  Nuclear factor-kappaB activation in airway epithelium induces inflammation and hyperresponsiveness.

Authors:  Cristen Pantano; Jennifer L Ather; John F Alcorn; Matthew E Poynter; Amy L Brown; Amy S Guala; Stacie L Beuschel; Gilman B Allen; Laurie A Whittaker; Mieke Bevelander; Charles G Irvin; Yvonne M W Janssen-Heininger
Journal:  Am J Respir Crit Care Med       Date:  2008-02-08       Impact factor: 21.405

10.  Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense.

Authors:  P Ye; F H Rodriguez; S Kanaly; K L Stocking; J Schurr; P Schwarzenberger; P Oliver; W Huang; P Zhang; J Zhang; J E Shellito; G J Bagby; S Nelson; K Charrier; J J Peschon; J K Kolls
Journal:  J Exp Med       Date:  2001-08-20       Impact factor: 14.307

View more
  7 in total

Review 1.  Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.

Authors:  Laurent Meijer; Deborah J Nelson; Vladimir Riazanski; Aida G Gabdoulkhakova; Geneviève Hery-Arnaud; Rozenn Le Berre; Nadège Loaëc; Nassima Oumata; Hervé Galons; Emmanuel Nowak; Laetitia Gueganton; Guillaume Dorothée; Michaela Prochazkova; Bradford Hall; Ashok B Kulkarni; Robert D Gray; Adriano G Rossi; Véronique Witko-Sarsat; Caroline Norez; Frédéric Becq; Denis Ravel; Dominique Mottier; Gilles Rault
Journal:  J Innate Immun       Date:  2016-03-18       Impact factor: 7.349

2.  Down-regulation of cytokine-induced interleukin-8 requires inhibition of p38 mitogen-activated protein kinase (MAPK) via MAPK phosphatase 1-dependent and -independent mechanisms.

Authors:  Nurlan Dauletbaev; Daniel Eklove; Nadir Mawji; Michele Iskandar; Sergio Di Marco; Imed-Eddine Gallouzi; Larry C Lands
Journal:  J Biol Chem       Date:  2011-03-15       Impact factor: 5.157

3.  Cystic fibrosis remodels the regulation of purinergic signaling by NTPDase1 (CD39) and NTPDase3.

Authors:  Michel Fausther; Julie Pelletier; Carla M Ribeiro; Jean Sévigny; Maryse Picher
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-02-26       Impact factor: 5.464

Review 4.  Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies.

Authors:  James L Kreindler
Journal:  Pharmacol Ther       Date:  2009-11-10       Impact factor: 12.310

5.  Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype.

Authors:  J P Clancy; S G Johnson; S W Yee; E M McDonagh; K E Caudle; T E Klein; M Cannavo; K M Giacomini
Journal:  Clin Pharmacol Ther       Date:  2014-03-05       Impact factor: 6.875

6.  The chitinase-like protein YKL-40 modulates cystic fibrosis lung disease.

Authors:  Andreas Hector; Michael S D Kormann; Ines Mack; Philipp Latzin; Carmen Casaulta; Elisabeth Kieninger; Zhe Zhou; Ali Ö Yildirim; Alexander Bohla; Nikolaus Rieber; Matthias Kappler; Barbara Koller; Ernst Eber; Olaf Eickmeier; Stefan Zielen; Oliver Eickelberg; Matthias Griese; Marcus A Mall; Dominik Hartl
Journal:  PLoS One       Date:  2011-09-20       Impact factor: 3.240

7.  Potential of anti-inflammatory treatment for cystic fibrosis lung disease.

Authors:  Jennifer L Taylor-Cousar; Kelsey A Von Kessel; Robert Young; David P Nichols
Journal:  J Inflamm Res       Date:  2010-08-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.